We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call detailed significant near-term financial deterioration driven by market disruption and policy-related clinician confusion: Q1 revenue fell 58% YoY, margins compressed sharply, and losses widened, prompting a material downgrade to full-year revenue guidance and a March restructuring. Offsetting these negatives are important strategic and clinical milestones — completion of a BLA submission for ReNu, a positive 170‑patient RCT for PuraPly AM, evidence of relative market share gains, disciplined cost reductions, and a solid cash position with no debt. While these highlights support longer-term confidence, they do not fully mitigate the severe short-term revenue and profitability declines and the uncertainty around CMS policy timing.
Organogenesis updated 2026 net revenue guidance to $270 million–$310 million (a decline of ~45%–52% YoY vs prior guidance of a 25%–38% decline), now anticipating first‑half revenue declines of roughly 52%–49% YoY with sequential improvement thereafter and strong third‑ and fourth‑quarter growth but a more measured recovery overall; the company expects positive adjusted EBITDA generation in H2 and a return to more normalized profitability in Q4, plans to reduce operating expenses (ex‑COGS) ~25% YoY for 2026 (including >30% YoY in H2) and assumes ~$7 million of Q3–Q4 restructuring savings as part of an approximate $14 million annualized cost reduction from the March restructuring (88 employee reduction and St. Petersburg facility closure); these outlooks are framed against Q1 results of $36.3 million net product revenue (down 58% YoY), Advanced Wound Care $29.5M (down 63%), Surgical & Sports Medicine $6.8M (flat), an adjusted EBITDA loss of $48.2M, cash of $92.1M, no debt and $75M revolver availability, and reflect continued uncertainty from CMS commentary affecting utilization.
On April 28 the company completed its BLA submission to the FDA for ReNu, a potential nonsurgical biologic for symptomatic knee osteoarthritis — a key regulatory milestone supporting future growth in a large unmet market.
A prospective, multicenter RCT of 170 patients evaluating PuraPly AM plus standard of care vs standard of care alone met its primary endpoint, demonstrating statistically significant wound closure at 12 weeks (p < 0.0477), reinforcing clinical evidence that may support future coverage.
Management reported that unit volumes outperformed industry declines and estimated core brands (excluding Apligraf) were down ~22% versus an estimated market contraction of ~63%, indicating relative share gains amid disruption.
Excluding inventory write-downs, non-GAAP gross profit was $14.8M, or 41% of net product revenue, vs GAAP gross profit of $10.5M (29%), showing underlying margin resilience absent discrete charges.
A March restructuring (88 employees and closure of St. Petersburg facility) is expected to yield approximately $14M of annualized cost reductions; additional estimated cost savings of ~$7M are expected in 3Q/4Q 2026.
Non-GAAP operating expenses (excluding cost of goods sold) were $80.3M versus $89.7M last year, a decrease of $9.4M or ~10% year-over-year, reflecting SG&A reductions.
Management reported month-to-month improvement into April, expects sequential revenue improvement through the year, and continues to target positive adjusted EBITDA generation in the second half of 2026 with normalized profitability in Q4.
As of March 31, 2026 the company held $92.1M in cash, cash equivalents and restricted cash (down slightly from $94.3M at December 31, 2025), had no outstanding debt and up to $75M availability under its revolving facility.
Welcome, ladies and gentlemen, to the First Quarter 2026 Earnings Conference Call for Organogenesis Holdings, Inc. [Operator Instructions] Please note that this conference call is being recorded, and the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors of the company's most recent annual report and its subsequently filed quarterly reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Re...